DOTA-PSMA-EB-01

DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM) .DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors[1]. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

Product Specifications

Product Name Alternative

LNC1003

UNSPSC

12352209

Target

PSMA; Radionuclide-Drug Conjugates (RDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dota-psma-eb-01.html

Purity

97.02

Solubility

DMSO : 6.67 mg/mL (ultrasonic)

Smiles

CC1=C(C=CC(C2=CC(C)=C(C=C2)NC([C@@H](NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)CCCCNC(CCOCCOCCC(NC[C@H]4CC[C@@H](CC4)C(N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC5=CC=C6C=CC=CC6=C5)=O)=O)=O)=O)=C1)/N=N/C7=C(C8=C(C(S(=O)(O)=O)=CC(S(=O)(O)=O)=C8N)C=C7)O

Molecular Formula

C87H115N15O28S2

Molecular Weight

1883.06

References & Citations

[1]Wen X, et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023 Jul;50 (9) :2846-2860.